Navigation Links
WPI receives award from Homeland Security Department to advance first-responder location
Date:10/29/2008

tems alert incident commanders when firefighters are in distressespecially when their stress levels put them at risk of a heart attack. A June 2008 report by the U.S. Fire Administration (USFA) identified stress or over-exhaustion and becoming lost or disoriented inside buildings as two of the top three leading causes of firefighter fatalities in 2007.

About WPI's Precision Personnel Technology

With more than $4 million in support from the U.S. Department of Justice, WPI has been working for five years on a precision indoor location system that uses advanced radio frequency technology and algorithms borrowed from synthetic aperture radar to pinpoint the three-dimensional location of a first responder wearing a special transmitter to within one foot. A $1 million grant from the Department of Homeland security in 2007 funded the integration of physiological monitoring capability into this system. This integration includes a vest made by Foster Miller Co. that monitors heart rate, respiration, body temperature, and posture, and a wireless pulse oximeter designed by WPI researchers that measures pulse, respiration, and blood oxygenation.

The DHS funds will permit the WPI research team to further explore enhancements designed to overcome known limitations of the existing radio-frequency and radar-based tracking technology. The team will explore augmenting the system with inertial navigation devices or other technologies that are not affected by shielding or reflectors and that can work in concert with the existing system to provide continuous, accurate location information under a wide range of building and environmental conditions.

About the Testing

To avoid a conflict of interest, WPI's systems will not be included in the national test, which will be conducted by NSRDEC and WPI in Boston in the spring of 2009. The WPI research team will begin work this year by cooperating with NSRDEC to identify the types of te
'/>"/>

Contact: Michael Dorsey
mwdorsey@wpi.edu
508-831-5609
Worcester Polytechnic Institute
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. CLARO Receives FDA-Clearance for Treatment of Acne
2. Local Organization Receives Multi-Million Dollar Grants for Natural Family Planning, HIV Testing and Family Planning Services for Men
3. St. Louis Local, Two-Time Breast Cancer Survivor Receives Courage Award
4. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
5. Air Methods Receives $17 Million Contract from Sikorsky Aircraft Company
6. Jefferson doctor receives Tree of Life award
7. LifeMasters Receives 2008 Vision Award for Business Impact
8. Worlds First Cattle Vaccine to Reduce E. coli O157 Threat Receives Full Licensing Approval in Canada
9. Aurora Health Cares Kradwell School Receives National Planetree Award
10. Rutgers receives $2.3 million federal grant to research use, safety of antipsychotics
11. China Sky One Medical, Inc. Receives Tax Refund
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3New H1N1 Flu Guide Offers Practical Tools and Tips for HR Professionals 61032 1New H1N1 Flu Guide Offers Practical Tools and Tips for HR Professionals 61032 2New H1N1 Flu Guide Offers Practical Tools and Tips for HR Professionals 61032 3Lung Cancer Alliance Staff and Advocates to Ring Closing Bell of New York Stock Exchange 28TM 29 61028 1Lung Cancer Alliance Staff and Advocates to Ring Closing Bell of New York Stock Exchange 28TM 29 61028 2PIA Says Inclusion of Agents in House Healthcare Bill is Positive But Concerns Remain 61024 1PIA Says Inclusion of Agents in House Healthcare Bill is Positive But Concerns Remain 61024 2PIA Says Inclusion of Agents in House Healthcare Bill is Positive But Concerns Remain 61024 3
Other Medicine Technology:MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting 10IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5